Monday, November 13, 2023
- 9:00AM-11:00AM
-
Abstract Number: 1439
Better Drug Retention on anti-IL17A Compared to Anti-TNF Therapy Despite Its Inferior Effect on Composite Joint Indexes and Quality of Life in Patients with PsA–analysis from the Czech Biologics Registry ATTRA
(1412–1441) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II: SpA- 9:00AM-11:00AM
-
Abstract Number: 1198
Bicycling Is Not Associated with New Knee Pain or Disease Progression over 48 Months in Those with Knee Osteoarthritis: Data from the Osteoarthritis Initiative
(1183–1199) Osteoarthritis – Clinical Poster II- 9:00AM-11:00AM
-
Abstract Number: 1433
Bimekizumab Impact on Core Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Domains for Patients with Psoriatic Arthritis: 52-Week Results from Four Phase 3 Studies
(1412–1441) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II: SpA- 9:00AM-11:00AM
-
Abstract Number: 1437
Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naïve Patients with Psoriatic Arthritis Who Were Responders at Week 16: Results from a Phase 3, Active-Reference Study
(1412–1441) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II: SpA- 9:00AM-11:00AM
-
Abstract Number: 1441
Bimekizumab Maintenance of Response and Safety in Patients with Moderate to Severe Plaque Psoriasis: Results from the Open-label Extension Period (Weeks 48–144) of the BE RADIANT Phase 3b Trial
(1412–1441) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II: SpA- 9:00AM-11:00AM
-
Abstract Number: 1415
Bimekizumab Treatment Impact on Work Productivity in Biologic DMARD‑Naïve and TNFi-IR Patients with Active Psoriatic Arthritis: Results up to 1 Year from Two Phase 3 Studies
(1412–1441) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II: SpA- 9:00AM-11:00AM
-
Abstract Number: 1066
Biologic Drug and Anti-Drug Antibody Monitoring: All 5 TNF-Inhibitors, Infliximab, Adalimumab, Golimumab, Etanercept, Certolizumab Pegol, in 63,930 Patient Samples
(1052–1081) Immunological Complications of Medical Therapy Poster- 9:00AM-11:00AM
-
Abstract Number: 1302
Biomarkers of Cardiovascular Risk in Patients with Rheumatoid Arthritis: Results from the TARGET Trial Biomarker Study
(1264–1307) RA – Diagnosis, Manifestations, and Outcomes Poster II- 9:00AM-11:00AM
-
Abstract Number: 1147
Blood-Based Biomarkers of Inflammation and Tissue Remodeling Can Discriminate Between Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis and Are Associated with Hand Function
(1124–1154) Miscellaneous Rheumatic & Inflammatory Diseases Poster II- 9:00AM-11:00AM
-
Abstract Number: 1465
Blood-dominant Disease in Older-onset Lupus: A Systematic Review and Meta-analysis
(1442–1487) SLE – Diagnosis, Manifestations, & Outcomes Poster II- 9:00AM-11:00AM
-
Abstract Number: 1300
Bone Marrow Edema in MRI Is More Associated with Rapid Radiographic Progression Than Clinically Relevant Radiographic Progression
(1264–1307) RA – Diagnosis, Manifestations, and Outcomes Poster II- 9:00AM-11:00AM
-
Abstract Number: 1364
Both Low and High 25(OH)-Vitamin D Levels Increase Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus
(1345–1364) Reproductive Issues in Rheumatic Disorders Poster II- 9:00AM-11:00AM
-
Abstract Number: 1176
Brepocitinib Prevents Type-I Interferon Induced Damage in Cultured Myocytes and Endothelial Cells Indicating a Potential Role in the Treatment of Dermatomyositis
(1155–1182) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II- 9:00AM-11:00AM
-
Abstract Number: 1509
Calcineurin Inhibitors for Treatment of Lupus Nephritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials